샘플 요청 목록

 카트 문의
시장보고서
상품코드
1799043

고립성 섬유종 치료 시장

Solitary Fibrous Tumor Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 279 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

고립성 섬유종 치료 세계 시장은 2030년까지 5,460만 달러에 달할 전망

2024년에 4,390만 달러로 추정되는 고립성 섬유종 치료 세계 시장은 분석 기간인 2024-2030년에 CAGR 3.7%로 성장하여 2030년에는 5,460만 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 외과 치료는 CAGR 3.5%를 기록하며 분석 기간 종료시에는 3,190만 달러에 달할 것으로 예측됩니다. 방사선 치료 분야의 성장률은 분석 기간 동안 CAGR 4.4%로 추정됩니다.

미국 시장은 1,200만 달러로 추정, 중국은 CAGR 6.8%로 성장 예측

미국의 고립성 섬유종 치료 시장은 2024년에 1,200만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 1,100만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 6.8%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.5%와 2.9%로 예측됩니다. 유럽에서는 독일이 CAGR 2.1%로 성장할 것으로 예측됩니다.

세계의 고립성 섬유종 치료 시장 - 주요 동향과 촉진요인 정리

고립성 섬유종 치료 : 정밀 종양학이 패러다임을 바꾼다?

고립성 섬유종(SFT)은 양성 또는 악성일 가능성이 있는 희귀한 간엽계 신생물로, 예측할 수 없는 특성으로 인해 진단, 치료 계획 및 장기적 관리에 심각한 문제를 야기합니다. 이러한 종양은 흉막에 가장 흔하게 발생하지만, 수막, 복부, 사지 등 다양한 흉막 외 부위에서도 확인되고 있습니다. SFT 관리의 중요한 트렌드는 병리조직학적 분석과 면역조직화학 마커가 진단 정확도 향상에 있어 중심적인 역할을 하고 있습니다. NAB2-STAT6 유전자 융합이 유전적 특징으로 확인되면서 진단이 비약적으로 정교해졌고, 향후 치료 표적으로 점점 더 많이 활용되고 있습니다. 각 기관에서 종양의 악성도, 크기, 전이 가능성에 따른 개별화된 접근법의 필요성이 인식되면서 치료 프로토콜은 빠르게 진화하고 있습니다.

외과적 절제술은 특히 절제 음성인 경우, 국소 종양에 대한 1차적인 근치적 선택이 될 수 있습니다. 그러나 고위험 조직학적 특징이나 불완전 절제술의 경우 방사선 치료나 전신요법 등의 보조적 치료가 고려되고 있습니다. 국소적이지만 수술이 불가능한 병변에 대한 정위적 방사선치료(SBRT)와 단절 양성 절제술에 대한 수술 후 보조 방사선치료에 대한 관심이 높아지고 있습니다. 화학요법의 효과는 제한적이지만, 테모졸로미드, 베바시주맙, 티로신키나아제 억제제 등의 병용요법이 검토되고 있습니다. 맞춤 종양학은 또한 유전체 프로파일링과 차세대 시퀀싱을 통해 특히 재발 및 전이 사례에서 표적 치료에 도움이 되는 실용적인 돌연변이를 발견함으로써 그 입지를 다져가고 있습니다.

새로운 치료법과 진단법이 환자의 결과를 바꿀 수 있을까?

최근 분자 병리학 및 영상 진단의 발전으로 고립성 섬유종의 검출 및 층화 현상이 현저하게 개선되고 있습니다. PET-CT, 조영제 MRI 및 동적 조영제 영상은 병기 분류 및 모니터링의 표준이 되고 있습니다. 또한, 순환 종양 DNA(ctDNA) 분석 및 기타 액체 생검법의 개발은 비침습적 질병 감시 및 재발을 조기에 발견할 수 있는 유망한 방법입니다. 면역요법, 특히 체크포인트 억제제는 진행성 또는 절제 불가능한 병변을 가진 SFT 환자를 대상으로도 평가되고 있습니다. 아직 초기 단계이지만, 결과는 유망하며, 전 세계적으로 여러 임상시험이 시작되었습니다.

또한, 분자 마커에 기반한 환자 맞춤형 치료 요법은 SFT와 같은 희귀 연부종양 관리 방식에 패러다임의 변화를 가져오고 있습니다. 종양위원회와 희귀질환 등록은 다학제적 논의를 촉진하고, 합의에 기반한 치료 계획을 통해 치료 결과를 개선하고 있습니다. 전 세계 SFT 코호트에서 얻은 데이터가 증가함에 따라 연구 개발은 위험에 기반한 알고리즘을 개발하여 최적의 모니터링 간격, 수술 전략, 보조 요법 옵션을 결정하고 있습니다. 이러한 데이터 기반의 개별화로 인해 오랫동안 치료 방침이 모호했던 SFT의 치료 전망이 크게 바뀌고 있습니다.

틈새 온콜로지 시장의 성장 원동력은?

고립성 섬유종 치료 시장의 성장은 진단 능력의 향상, 임상의의 인식 증가, 표적 치료 및 정밀 의료의 발전과 관련된 여러 요인에 의해 이루어집니다. 주요 요인 중 하나는 SFT를 정확하게 식별하고 조직학적으로 유사한 종양과 구별할 수 있는 고급 진단 양식의 가용성 및 사용의 증가입니다. 이를 통해 보다 정확한 병기 분류와 조기 치료 시작이 가능해졌습니다. 또한, 유전체 분석 도구가 임상에 도입되면서 종양 생물학에 기반한 맞춤형 치료가 가능해졌고, 환자의 예후를 개선할 수 있게 되었습니다.

육종 전문 치료센터와 희귀암 네트워크 구축도 중요한 요소입니다. 이러한 전문 시설은 전문 지식과 실험적 치료에 대한 접근성을 향상시킬 뿐만 아니라 환자 등록 및 임상시험 파이프라인에도 기여하고 있습니다. 특히 희귀암과 연부육종에 대한 연구비 증가는 약품 개발의 촉매제가 되어 치료 선택의 폭을 넓혀주고 있습니다. 또한, 관찰 연구와 장기 추적 조사에서 데이터가 축적됨에 따라 예측 모델과 치료 알고리즘이 임상의의 근거에 기반한 의사결정에 도움을 주고 있습니다. 이러한 요소들이 결합되어 전 세계 SFT 환자들을 위한 견고하고 진화된 치료 생태계의 개발을 촉진하고 있습니다.

부문

치료(수술 치료, 방사선 치료 치료, 보조 화학요법 치료), 최종사용자(외래 수술 센터 최종사용자, 병원 최종사용자, 기타 최종사용자)

조사 대상 기업 사례

  • Aadi Bioscience, Inc.
  • ADC Therapeutics SA
  • Advenchen Laboratories LLC
  • Arog Pharmaceuticals
  • AVEO Pharmaceuticals
  • Bayer AG
  • BeOne Medicines(formerly BeiGene)
  • Bristol-Myers Squibb Co
  • Chia Tai Tianqing Pharma
  • Chugai Pharma France
  • CytRx
  • Epizyme, Inc.
  • Gradalis, Inc.
  • Incyte Corporation
  • Iovance Biotherapeutics
  • Nanobiotix(Nanobiotix SA)
  • Novartis AG
  • Philogen S.p.A.
  • Plus Therapeutics, Inc.
  • Telix Pharmaceuticals Ltd

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계 고유의 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가가 선별한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.09.04

Global Solitary Fibrous Tumor Treatment Market to Reach US$54.6 Million by 2030

The global market for Solitary Fibrous Tumor Treatment estimated at US$43.9 Million in the year 2024, is expected to reach US$54.6 Million by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Surgery Treatment, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$31.9 Million by the end of the analysis period. Growth in the Radiation Therapy Treatment segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.0 Million While China is Forecast to Grow at 6.8% CAGR

The Solitary Fibrous Tumor Treatment market in the U.S. is estimated at US$12.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$11.0 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Solitary Fibrous Tumor Treatment Market - Key Trends & Drivers Summarized

Solitary Fibrous Tumor Treatment: Is Precision Oncology Changing the Paradigm?

Solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms that may be benign or malignant, and their unpredictable nature presents significant challenges in diagnosis, treatment planning, and long-term management. These tumors most commonly arise in the pleura but have also been identified in various extrapleural sites such as the meninges, abdomen, and extremities. A key trend in SFT management is the central role of histopathological analysis and immunohistochemical markers in improving diagnostic accuracy. The identification of the NAB2-STAT6 gene fusion as a genetic hallmark has significantly refined diagnosis and is increasingly used as a target for future therapies. Treatment protocols are evolving rapidly as institutions recognize the need for individualized approaches based on tumor grade, size, and metastatic potential.

Surgical resection remains the primary curative option for localized tumors, especially when negative margins are achieved. However, in cases of high-risk histological features or incomplete excision, adjunctive treatments such as radiotherapy and systemic therapies are being explored. There is growing interest in stereotactic body radiotherapy (SBRT) for localized but inoperable lesions, and in adjuvant radiation for margin-positive resections. Chemotherapy has shown limited efficacy, but combination regimens involving temozolomide, bevacizumab, and tyrosine kinase inhibitors are under investigation. Personalized oncology is also making its mark through genomic profiling and next-generation sequencing to uncover actionable mutations that could inform targeted therapies, particularly in recurrent or metastatic cases.

Are Emerging Therapies and Diagnostics Reshaping Patient Outcomes?

Recent advancements in molecular pathology and imaging are significantly improving the detection and stratification of solitary fibrous tumors. PET-CT, MRI with contrast, and dynamic contrast-enhanced imaging are becoming standard for staging and monitoring. Additionally, the development of circulating tumor DNA (ctDNA) assays and other liquid biopsy methods offer promise for non-invasive disease surveillance and early detection of recurrence. Immunotherapy, particularly checkpoint inhibitors, is also being evaluated in SFT patients with aggressive or unresectable disease profiles. While still in early phases, results are encouraging and have sparked multiple clinical trials worldwide.

Further, patient-specific treatment regimens based on molecular markers are driving a paradigm shift in how rare soft-tissue tumors like SFT are managed. Tumor boards and rare disease registries are facilitating multi-disciplinary discussions and improving outcomes through consensus-driven treatment planning. As more data becomes available from global SFT cohorts, researchers are developing risk-based algorithms to determine optimal surveillance intervals, surgical strategies, and adjuvant therapy options. Such data-driven personalization is transforming the therapeutic outlook for a condition that has long suffered from ambiguous treatment pathways.

What Is Fueling the Growth in This Niche Oncology Market?

The growth in the solitary fibrous tumor treatment market is driven by several factors related to improved diagnostic capabilities, rising awareness among clinicians, and advancements in targeted and precision medicine. One primary driver is the increasing availability and use of advanced diagnostic modalities that can accurately identify SFTs and differentiate them from histologically similar tumors. This has led to more accurate staging and earlier treatment initiation. Additionally, the integration of genomic tools into clinical practice has empowered oncologists to customize therapies based on tumor biology, resulting in better patient outcomes.

The establishment of dedicated sarcoma treatment centers and rare cancer networks is another critical factor. These specialized facilities not only enhance access to expertise and experimental therapies but also contribute to patient registries and clinical trial pipelines. An increase in research funding, particularly into rare cancers and soft-tissue sarcomas, is catalyzing drug development and expanding treatment options. Furthermore, as data accumulates from observational studies and long-term follow-ups, predictive models and treatment algorithms are helping clinicians make evidence-based decisions. Together, these elements are driving the development of a robust and evolving treatment ecosystem for SFT patients worldwide.

SCOPE OF STUDY:

The report analyzes the Solitary Fibrous Tumor Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Surgery Treatment, Radiation Therapy Treatment, Adjuvant Chemotherapy Treatment); End-User (Ambulatory Surgery Centers End-User, Hospitals End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Aadi Bioscience, Inc.
  • ADC Therapeutics SA
  • Advenchen Laboratories LLC
  • Arog Pharmaceuticals
  • AVEO Pharmaceuticals
  • Bayer AG
  • BeOne Medicines (formerly BeiGene)
  • Bristol-Myers Squibb Co
  • Chia Tai Tianqing Pharma
  • Chugai Pharma France
  • CytRx
  • Epizyme, Inc.
  • Gradalis, Inc.
  • Incyte Corporation
  • Iovance Biotherapeutics
  • Nanobiotix (Nanobiotix SA)
  • Novartis AG
  • Philogen S.p.A.
  • Plus Therapeutics, Inc.
  • Telix Pharmaceuticals Ltd

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Solitary Fibrous Tumor Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Clinical Recognition of Rare Tumors Spurs Research and Diagnostic Efforts in SFT
    • Rising Use of Targeted Therapy and Tyrosine Kinase Inhibitors Propels Drug Development for SFT
    • Expansion of Genomic Profiling and Tumor Marker Identification Strengthens Precision Medicine Approaches
    • Advanced Imaging Modalities Improve Early Detection and Surgical Planning for Solitary Fibrous Tumors
    • Growing Role of Immunotherapy in Soft Tissue Sarcomas Generates Pipeline Activity in SFT Space
    • Clinical Trial Expansion for Rare Tumors Opens Funding and Access to Experimental Therapies
    • Surge in Tertiary Oncology Centers Enhances Access to Multimodal SFT Treatment Protocols
    • Digital Pathology and AI-Based Histology Support Early and Accurate SFT Diagnosis
    • Increased Advocacy for Rare Cancer Awareness Drives Inclusion in National Cancer Registries
    • Combination Therapy Regimens and Off-Label Use Trends Expand Offshoot Markets for Adjunct Treatments
    • Global Collaboration in Rare Disease Research Supports Regulatory Acceleration and Orphan Drug Status
    • Minimally Invasive Surgical Advancements Propel Demand for Improved Preoperative Planning Tools
    • Real-World Evidence Generation and Biomarker Discovery Sustain Long-Term Research and Investment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Solitary Fibrous Tumor Treatment Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Solitary Fibrous Tumor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Solitary Fibrous Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Radiation Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Adjuvant Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Adjuvant Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Adjuvant Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ambulatory Surgery Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Ambulatory Surgery Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • JAPAN
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CHINA
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • EUROPE
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Solitary Fibrous Tumor Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Solitary Fibrous Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • FRANCE
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • GERMANY
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Solitary Fibrous Tumor Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Solitary Fibrous Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • INDIA
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Solitary Fibrous Tumor Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Solitary Fibrous Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Solitary Fibrous Tumor Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Solitary Fibrous Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AFRICA
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제